United Kingdom authorizes first CRISPR-based medicine

The United Kingdom's Medicines and Healthcare products Regulatory Agency authorized Casgevy on 16 November 2023, making it the first medicine using CRISPR gene-editing technology to receive regulatory approval. The treatment was cleared for specified patients with sickle cell disease and transfusion-dependent beta thalassemia.

Clinicians collect a patient's blood-forming stem cells, edit a regulatory region to increase production of fetal haemoglobin and return the cells after conditioning chemotherapy. The edit occurs outside the body and is not intended to alter reproductive cells or pass changes to future generations.

Clinical trials showed that many treated participants avoided severe pain crises or regular transfusions during the reported follow-up. The procedure is intensive, carries risks from conditioning and requires specialized facilities. Approval does not mean it is appropriate, affordable or immediately available to every patient with either condition.

The MHRA decision assessed quality, safety and efficacy for the indicated population. Health-technology assessment, pricing and National Health Service access followed separate processes. Longer follow-up remains important for durability and potential rare effects.

This item records the regulatory milestone, not the invention of CRISPR or the first experimental use. It uses the medicine's authorized claims rather than calling it a universal cure. The significance lies in moving a genome-editing approach from trial into licensed clinical practice under defined conditions.